BioSpace News Archive

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause.

Ocean Biomedical, Inc. announced today that an equity analyst coverage report issued by Fundamental Research Corp. (“FRC”) has increased FRC’s price target of OCEA stock to $17.63 per share, up from FRC’s initial report in March 2023 of $16.40.

Virion Therapeutics, LLC today, presented data entitled “Intrahepatic CD8 + T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model” at the European Association for the Study of Liver Diseases (EASL) annual Congress.

Mozart Therapeutics today announced the presentation of preclinical pharmacologic and tolerability data for MTX-101, a bispecific autoimmune checkpoint inhibitor, at the Annual Meeting of the Federation of Clinical Immunology Societies.

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced that it is investigating the use of its Hemopurifier® in the organ transplant market, in addition to its ongoing studies in cancer and COVID-19.

Quest Diagnostics today announced that it has completed its previously announced acquisition of Haystack Oncology.

Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a cooperative research and development agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS).

The University of Tennessee Health Science Center (UTHSC), oncology drug discovery research partner to Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, has secured two additional grants to develop oncology therapeutics for indications of high unmet need.

SAB Biotherapeutics today announced the presentation of positive safety and pharmacologic data from a GLP toxicology study for SAB-142, a first in class fully human immunotherapeutic being developed for delaying onset and progression of Type 1 Diabetes (T1D), at the Federation of Clinical Immunology Societies (FOCIS) in Boston.

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia.